Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand to Report Fourth Quarter and Full Year 2018 Results on February 7th

Read More

Ligand Introduces 2019 Financial Outlook and Raises 2018 Financial Guidance

Read More

Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics

Read More

Recent Events

Upcoming Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range